[{"quiz_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed127", "question_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed127-001", "question": "A 58-year-old woman with hypertrophic cardiomyopathy presents with progressive dyspnea and New York Heart Association class III symptoms despite maximum tolerated doses of metoprolol and verapamil. Echocardiography reveals a resting left ventricular outflow tract (LVOT) gradient of 85 mmHg, septal thickness of 22 mm, and systolic anterior motion of the mitral valve with moderate mitral regurgitation. She has no coronary artery disease on angiography. The septal perforator anatomy is suitable for intervention. Which of the following findings would most strongly favor surgical myectomy over alcohol septal ablation in this patient?", "options": ["Concomitant intrinsic mitral valve disease requiring repair", "Patient preference for less invasive procedure", "Presence of atrial fibrillation requiring maze procedure consideration", "Septal thickness greater than 20 mm", "Age greater than 55 years"], "answer": "A", "answer_index": 0, "explanation": "Surgical myectomy is preferred over alcohol septal ablation when concomitant cardiac pathology requiring surgical correction exists, such as intrinsic mitral valve disease (leaflet abnormalities, chordal pathology) needing repair or replacement. While septal thickness >30mm and unsuitable coronary anatomy favor surgery, 22mm thickness alone does not preclude ablation. Atrial fibrillation can be addressed with catheter ablation. Age and patient preference, while considerations, are not absolute indications for one approach over another.", "generator_model": "claude-opus-4-5-20251101", "seed": 127, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "gpt-5.1-2025-11-13", "judge_model_outputs_raw": "{\"analysis\":\"Validity label: V\\nVerdict on keyed answer: Correct best\\nKey stem clues: Symptomatic obstructive hypertrophic cardiomyopathy (NYHA III) refractory to maximal medical therapy, high resting LVOT gradient (85 mmHg), septal thickness 22 mm, suitable septal perforator anatomy for alcohol ablation, and question asks which additional finding would most strongly favor surgical myectomy instead of ablation.\\nChoice A (concomitant intrinsic mitral valve disease requiring repair) correctly reflects guideline-based indications: presence of other surgically correctable cardiac pathology (e.g., intrinsic mitral disease, papillary muscle/chordal abnormalities) is a strong indication for surgical septal myectomy rather than alcohol septal ablation. Other options: B (patient preference for less invasive procedure) actually favors ablation, not surgery; C (AF needing maze) is less strong because AF can be managed with catheter ablation and is not a primary determinant of septal reduction modality; D (septal thickness >20 mm) is common in HCM and does not, by itself, push toward myectomy over ablation; E (age >55) does not favor myectomy—if anything, alcohol ablation is often considered more in older patients. No internal contradictions or underspecification. Teaching point and explanation are accurate and contemporary.\\nMinimal fix: None required; item is already unambiguous and accurate.\",\"medical_accuracy_score\":\"5\",\"logical_validity\":true,\"logical_false_reason\":\"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V\nVerdict on keyed answer: Correct best\nKey stem clues: Symptomatic obstructive hypertrophic cardiomyopathy (NYHA III) refractory to maximal medical therapy, high resting LVOT gradient (85 mmHg), septal thickness 22 mm, suitable septal perforator anatomy for alcohol ablation, and question asks which additional finding would most strongly favor surgical myectomy instead of ablation.\nChoice A (concomitant intrinsic mitral valve disease requiring repair) correctly reflects guideline-based indications: presence of other surgically correctable cardiac pathology (e.g., intrinsic mitral disease, papillary muscle/chordal abnormalities) is a strong indication for surgical septal myectomy rather than alcohol septal ablation. Other options: B (patient preference for less invasive procedure) actually favors ablation, not surgery; C (AF needing maze) is less strong because AF can be managed with catheter ablation and is not a primary determinant of septal reduction modality; D (septal thickness >20 mm) is common in HCM and does not, by itself, push toward myectomy over ablation; E (age >55) does not favor myectomy—if anything, alcohol ablation is often considered more in older patients. No internal contradictions or underspecification. Teaching point and explanation are accurate and contemporary.\nMinimal fix: None required; item is already unambiguous and accurate.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed127", "question_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed127-002", "question": "A 6-year-old boy presents with recurrent episodes of weakness and dark urine following viral illnesses. Laboratory studies during an acute episode show: serum creatine kinase 45,000 U/L, myoglobinuria, and non-ketotic hypoglycemia with inappropriately low free fatty acids. Acylcarnitine profile shows elevated C14:1 and C14:2 species. Genetic testing confirms compound heterozygous mutations in ACADVL. Which of the following dietary modifications is most critical for preventing future metabolic crises?", "options": ["Strict avoidance of medium-chain triglycerides", "Supplementation with odd-chain fatty acids", "Restriction of long-chain fatty acids with medium-chain triglyceride supplementation", "High-protein diet with branched-chain amino acid supplementation", "Carnitine supplementation with unrestricted fat intake"], "answer": "C", "answer_index": 2, "explanation": "ACADVL mutations cause very long-chain acyl-CoA dehydrogenase (VLCAD) deficiency, a disorder of long-chain fatty acid oxidation. Management requires restriction of long-chain fatty acids (which cannot be metabolized) and supplementation with medium-chain triglycerides (MCTs), which bypass the defective enzyme and provide an alternative energy source. MCT avoidance would be harmful. Carnitine supplementation alone without dietary modification is insufficient, and high-protein diets do not address the underlying metabolic defect.", "generator_model": "claude-opus-4-5-20251101", "seed": 127, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "gpt-5.1-2025-11-13", "judge_model_outputs_raw": "{\"analysis\":\"Validity label: V\\nVerdict on keyed answer: Correct best\\nKey stem clues: Child with recurrent rhabdomyolysis (elevated CK, myoglobinuria) triggered by illness, non-ketotic hypoglycemia with low free fatty acids, acylcarnitine profile with elevated C14:1 and C14:2, and confirmed biallelic ACADVL mutations → very long-chain acyl-CoA dehydrogenase (VLCAD) deficiency. Standard management of long-chain FAO defects emphasizes avoidance of prolonged fasting, restriction of long-chain triglycerides, and provision of medium-chain triglycerides (which bypass the block). Thus option C (restriction of long-chain fatty acids with MCT supplementation) directly addresses the pathophysiology and matches current metabolic guidelines.\\nOther options: A (strict avoidance of MCTs) is contraindicated because MCTs are a key alternative fuel source. B (odd-chain fatty acids) is not standard preventive therapy for VLCAD. D (high-protein, BCAA supplementation) targets different metabolic disorders (e.g., MSUD) and not FAO. E (carnitine supplementation with unrestricted fat) fails to restrict the problematic long-chain fats and carnitine is not primary therapy in VLCAD and may even be used cautiously.\\nMain medical issues: None significant; item is accurate and focused.\\nMinimal fix: Add “and avoidance of prolonged fasting” as an additional management element or answer choice for even greater realism/clarity.\",\"medical_accuracy_score\":\"5\",\"logical_validity\":true,\"logical_false_reason\":\"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V\nVerdict on keyed answer: Correct best\nKey stem clues: Child with recurrent rhabdomyolysis (elevated CK, myoglobinuria) triggered by illness, non-ketotic hypoglycemia with low free fatty acids, acylcarnitine profile with elevated C14:1 and C14:2, and confirmed biallelic ACADVL mutations → very long-chain acyl-CoA dehydrogenase (VLCAD) deficiency. Standard management of long-chain FAO defects emphasizes avoidance of prolonged fasting, restriction of long-chain triglycerides, and provision of medium-chain triglycerides (which bypass the block). Thus option C (restriction of long-chain fatty acids with MCT supplementation) directly addresses the pathophysiology and matches current metabolic guidelines.\nOther options: A (strict avoidance of MCTs) is contraindicated because MCTs are a key alternative fuel source. B (odd-chain fatty acids) is not standard preventive therapy for VLCAD. D (high-protein, BCAA supplementation) targets different metabolic disorders (e.g., MSUD) and not FAO. E (carnitine supplementation with unrestricted fat) fails to restrict the problematic long-chain fats and carnitine is not primary therapy in VLCAD and may even be used cautiously.\nMain medical issues: None significant; item is accurate and focused.\nMinimal fix: Add “and avoidance of prolonged fasting” as an additional management element or answer choice for even greater realism/clarity.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed127", "question_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed127-003", "question": "A 34-year-old woman with systemic lupus erythematosus on hydroxychloroquine and mycophenolate presents with acute onset severe headache, confusion, and seizures. Blood pressure is 168/102 mmHg. MRI brain shows bilateral posterior white matter T2/FLAIR hyperintensities without restricted diffusion. Lumbar puncture shows normal opening pressure, 8 WBC/μL (lymphocyte predominant), protein 52 mg/dL, and negative cultures. Anti-ribosomal P antibodies are positive. Which additional finding would most strongly suggest neuropsychiatric lupus rather than posterior reversible encephalopathy syndrome (PRES)?", "options": ["Presence of anti-dsDNA antibodies at high titer", "Low complement C3 and C4 levels", "Elevated CSF IgG index with oligoclonal bands", "Resolution of MRI findings with blood pressure control", "Concurrent lupus nephritis flare"], "answer": "C", "answer_index": 2, "explanation": "Elevated CSF IgG index with oligoclonal bands indicates intrathecal immunoglobulin synthesis, strongly supporting CNS inflammation from neuropsychiatric lupus (NPSLE) rather than PRES, which is a vasogenic edema syndrome without primary CNS inflammation. Anti-dsDNA antibodies and low complements indicate systemic lupus activity but don't differentiate CNS involvement. Resolution with BP control would actually favor PRES. Concurrent nephritis indicates systemic activity but doesn't confirm CNS-specific disease.", "generator_model": "claude-opus-4-5-20251101", "seed": 127, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "gpt-5.1-2025-11-13", "judge_model_outputs_raw": "{\"analysis\":\"Validity label: V\\nVerdict on keyed answer: Correct best\\nKey stem clues: Known SLE on immunosuppression; acute severe headache, confusion, seizures; hypertension; MRI with bilateral posterior white-matter T2/FLAIR hyperintensities without diffusion restriction (classic PRES pattern); LP with mild lymphocytic pleocytosis and mildly elevated protein but negative cultures; positive anti–ribosomal P antibodies (associated with NPSLE). The question asks what *additional* finding would most strongly support NPSLE over PRES.\\nOption C (elevated CSF IgG index with oligoclonal bands) directly indicates intrathecal immune activation and CNS inflammation, fitting NPSLE and not expected in PRES, making it the single best discriminator. A, B, and E reflect systemic lupus activity (and can coexist with PRES during SLE flares) and thus do not clearly distinguish NPSLE from PRES. D (resolution with BP control) would actually argue for PRES, not NPSLE, and is therefore opposite of what is asked.\\nNo internal contradictions or underspecification are evident; one best answer is clear and the key matches it.\\nMinimal fix: Clarify in the stem that current medications and renal status are unchanged to further emphasize the diagnostic dilemma, though not strictly necessary for validity.\",\"medical_accuracy_score\":\"5\",\"logical_validity\":true,\"logical_false_reason\":\"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V\nVerdict on keyed answer: Correct best\nKey stem clues: Known SLE on immunosuppression; acute severe headache, confusion, seizures; hypertension; MRI with bilateral posterior white-matter T2/FLAIR hyperintensities without diffusion restriction (classic PRES pattern); LP with mild lymphocytic pleocytosis and mildly elevated protein but negative cultures; positive anti–ribosomal P antibodies (associated with NPSLE). The question asks what *additional* finding would most strongly support NPSLE over PRES.\nOption C (elevated CSF IgG index with oligoclonal bands) directly indicates intrathecal immune activation and CNS inflammation, fitting NPSLE and not expected in PRES, making it the single best discriminator. A, B, and E reflect systemic lupus activity (and can coexist with PRES during SLE flares) and thus do not clearly distinguish NPSLE from PRES. D (resolution with BP control) would actually argue for PRES, not NPSLE, and is therefore opposite of what is asked.\nNo internal contradictions or underspecification are evident; one best answer is clear and the key matches it.\nMinimal fix: Clarify in the stem that current medications and renal status are unchanged to further emphasize the diagnostic dilemma, though not strictly necessary for validity.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed127", "question_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed127-004", "question": "A 52-year-old man with type 2 diabetes presents for evaluation of recurrent hypoglycemia occurring 3-4 hours postprandially. He underwent Roux-en-Y gastric bypass 2 years ago with 45 kg weight loss. During a symptomatic episode, laboratory studies show: glucose 38 mg/dL, insulin 45 μU/mL (elevated), C-peptide 8.2 ng/mL (elevated), proinsulin 22 pmol/L (elevated), and negative sulfonylurea screen. Calcium-stimulated angiography localizes insulin secretion to the body and tail of the pancreas. Which of the following is the most appropriate next step in management?", "options": ["Distal pancreatectomy", "Diazoxide therapy", "Octreotide therapy", "Dietary modification with acarbose", "Enucleation of insulinoma"], "answer": "D", "answer_index": 3, "explanation": "This presentation is classic for post-gastric bypass hyperinsulinemic hypoglycemia (nesidioblastosis/non-insulinoma pancreatogenous hypoglycemia syndrome). Unlike insulinoma, this involves diffuse islet cell hyperfunction. First-line management is dietary modification (low glycemic index, frequent small meals) combined with acarbose to slow carbohydrate absorption and blunt the exaggerated incretin response. Distal pancreatectomy is reserved for refractory cases. The diffuse localization on angiography and post-bypass context argue against focal insulinoma requiring enucleation.", "generator_model": "claude-opus-4-5-20251101", "seed": 127, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "gpt-5.1-2025-11-13", "judge_model_outputs_raw": "{\"analysis\":\"Validity label: V\\nVerdict on keyed answer: Correct best\\nKey stem clues: Post–Roux-en-Y gastric bypass patient, 3–4 hour postprandial symptomatic hypoglycemia, inappropriately elevated insulin/C‑peptide/proinsulin, negative sulfonylurea screen, and calcium-stimulated angiography showing diffuse insulin secretion from body and tail rather than a focal lesion. This pattern after bariatric surgery is characteristic of non–insulinoma pancreatogenous hypoglycemia (nesidioblastosis/post-bypass hyperinsulinemic hypoglycemia).\\nDistal pancreatectomy (A) is used for severe, refractory disease—not first-line. Diazoxide (B) and octreotide (C) are second-line pharmacologic options for refractory cases; guidelines and reviews emphasize initial conservative therapy with dietary modification and alpha-glucosidase inhibition (acarbose). Enucleation of insulinoma (E) is inappropriate because imaging/angiography suggests diffuse rather than focal disease and the temporal relationship to gastric bypass favors nesidioblastosis over insulinoma.\\nThe keyed answer D (dietary modification with acarbose) correctly reflects first-line management and is the most appropriate next step.\\nMain medical accuracy: The pathophysiology and management sequencing are accurate and consistent with current understanding of post-bariatric hyperinsulinemic hypoglycemia.\\nMinimal fix: Clarify in the stem that cross-sectional imaging failed to identify a discrete pancreatic mass, further excluding focal insulinoma and reinforcing diffuse disease, though this is already strongly implied.\\n\",\"medical_accuracy_score\":\"5\",\"logical_validity\":true,\"logical_false_reason\":\"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V\nVerdict on keyed answer: Correct best\nKey stem clues: Post–Roux-en-Y gastric bypass patient, 3–4 hour postprandial symptomatic hypoglycemia, inappropriately elevated insulin/C‑peptide/proinsulin, negative sulfonylurea screen, and calcium-stimulated angiography showing diffuse insulin secretion from body and tail rather than a focal lesion. This pattern after bariatric surgery is characteristic of non–insulinoma pancreatogenous hypoglycemia (nesidioblastosis/post-bypass hyperinsulinemic hypoglycemia).\nDistal pancreatectomy (A) is used for severe, refractory disease—not first-line. Diazoxide (B) and octreotide (C) are second-line pharmacologic options for refractory cases; guidelines and reviews emphasize initial conservative therapy with dietary modification and alpha-glucosidase inhibition (acarbose). Enucleation of insulinoma (E) is inappropriate because imaging/angiography suggests diffuse rather than focal disease and the temporal relationship to gastric bypass favors nesidioblastosis over insulinoma.\nThe keyed answer D (dietary modification with acarbose) correctly reflects first-line management and is the most appropriate next step.\nMain medical accuracy: The pathophysiology and management sequencing are accurate and consistent with current understanding of post-bariatric hyperinsulinemic hypoglycemia.\nMinimal fix: Clarify in the stem that cross-sectional imaging failed to identify a discrete pancreatic mass, further excluding focal insulinoma and reinforcing diffuse disease, though this is already strongly implied.\n", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed127", "question_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed127-005", "question": "A 3-week-old male infant presents with poor feeding, lethargy, and hypotonia. He was born at term following an uncomplicated pregnancy. Physical examination reveals hepatomegaly, hypotonia, and macroglossia. Echocardiography shows severe biventricular hypertrophy with a left ventricular ejection fraction of 25%. Laboratory studies show elevated creatine kinase and AST. Urine organic acids are normal. Enzyme assay on dried blood spot shows markedly reduced acid alpha-glucosidase activity. Genetic testing confirms two pathogenic variants in GAA. Which of the following factors is most predictive of poor response to enzyme replacement therapy?", "options": ["Presence of cardiomyopathy at diagnosis", "Cross-reactive immunologic material (CRIM) negative status", "Age at diagnosis less than 1 month", "Elevated creatine kinase level", "Presence of macroglossia"], "answer": "B", "answer_index": 1, "explanation": "In infantile-onset Pompe disease, CRIM-negative status (complete absence of endogenous GAA protein) is the strongest predictor of poor response to enzyme replacement therapy (ERT) due to development of high-sustained antibody titers against the recombinant enzyme, which neutralize therapeutic effect. CRIM-negative patients require immune tolerance induction protocols. While early cardiomyopathy and young age at diagnosis indicate severe disease, CRIM-positive patients with these features can still respond well to ERT. Elevated CK and macroglossia are disease markers but not predictive of treatment response.", "generator_model": "claude-opus-4-5-20251101", "seed": 127, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "gpt-5.1-2025-11-13", "judge_model_outputs_raw": "{\"analysis\":\"Validity label: V\\nVerdict on keyed answer: Correct best\\nKey stem clues: 3‑week-old infant; hypotonia, macroglossia, hepatomegaly; severe hypertrophic cardiomyopathy with low EF; elevated CK/AST; normal urine organic acids; markedly reduced acid alpha‑glucosidase activity; confirmed biallelic GAA variants—classic infantile-onset Pompe disease. Question asks which factor is most predictive of poor response to enzyme replacement therapy (ERT). In current Pompe literature and guidelines, cross-reactive immunologic material (CRIM)-negative status is the major determinant of poor ERT response because complete absence of endogenous GAA predisposes to high, sustained anti-drug antibody titers that neutralize therapy. Other options (presence of cardiomyopathy, age <1 month, elevated CK, macroglossia) correlate with disease severity but are not independently the main predictor of ERT response; early diagnosis can actually improve outcome. No internal contradictions or underspecification; a single best answer clearly exists and matches the key.\\nMain medical accuracy issue(s): None apparent; explanation is consistent with standard Pompe management.\\nMinimal fix: Add explicit statement in stem such as “CRIM status is pending” to cue why the question focuses on predictors of ERT response, though not strictly necessary for validity.\",\"medical_accuracy_score\":\"5\",\"logical_validity\":true,\"logical_false_reason\":\"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V\nVerdict on keyed answer: Correct best\nKey stem clues: 3‑week-old infant; hypotonia, macroglossia, hepatomegaly; severe hypertrophic cardiomyopathy with low EF; elevated CK/AST; normal urine organic acids; markedly reduced acid alpha‑glucosidase activity; confirmed biallelic GAA variants—classic infantile-onset Pompe disease. Question asks which factor is most predictive of poor response to enzyme replacement therapy (ERT). In current Pompe literature and guidelines, cross-reactive immunologic material (CRIM)-negative status is the major determinant of poor ERT response because complete absence of endogenous GAA predisposes to high, sustained anti-drug antibody titers that neutralize therapy. Other options (presence of cardiomyopathy, age <1 month, elevated CK, macroglossia) correlate with disease severity but are not independently the main predictor of ERT response; early diagnosis can actually improve outcome. No internal contradictions or underspecification; a single best answer clearly exists and matches the key.\nMain medical accuracy issue(s): None apparent; explanation is consistent with standard Pompe management.\nMinimal fix: Add explicit statement in stem such as “CRIM status is pending” to cue why the question focuses on predictors of ERT response, though not strictly necessary for validity.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed127", "question_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed127-006", "question": "A 67-year-old man with ischemic cardiomyopathy (LVEF 28%) and an implantable cardioverter-defibrillator presents after receiving three appropriate shocks for ventricular tachycardia over 24 hours despite amiodarone 400 mg daily. He is hemodynamically stable with blood pressure 102/68 mmHg. ECG shows sinus rhythm at 72 bpm with QTc 485 ms. Electrolytes and thyroid function are normal. Device interrogation confirms monomorphic VT at 188 bpm terminated by ATP and shocks. Which of the following is the most appropriate next step?", "options": ["Increase amiodarone to 600 mg daily", "Add mexiletine 200 mg three times daily", "Urgent catheter ablation of ventricular tachycardia", "Initiate dofetilide after appropriate QTc assessment", "Add ranolazine 500 mg twice daily"], "answer": "C", "answer_index": 2, "explanation": "This patient has electrical storm (≥3 sustained VT/VF episodes in 24 hours) refractory to amiodarone, which is a class I indication for urgent catheter ablation per current guidelines. Increasing amiodarone risks toxicity and QT prolongation. Adding mexiletine is reasonable for adjunctive therapy but does not address the substrate. Dofetilide is contraindicated with QTc >440ms in men and in the acute setting. Ranolazine has limited evidence for VT suppression. Catheter ablation targeting the VT substrate offers the best chance of preventing recurrent episodes.", "generator_model": "claude-opus-4-5-20251101", "seed": 127, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "gpt-5.1-2025-11-13", "judge_model_outputs_raw": "{\"analysis\":\"Validity label: V\\nVerdict on keyed answer: Correct best\\nKey stem clues: Ischemic cardiomyopathy with severely reduced LVEF (28%), ICD in place, three appropriate therapies for monomorphic VT over 24 hours, already on substantial-dose amiodarone (400 mg/d), hemodynamically stable, QTc 485 ms, normal electrolytes and thyroid. These define electrical storm refractory to amiodarone in a structural heart disease patient.\\nCatheter ablation (C) is guideline-supported as a class I indication for patients with electrical storm or recurrent ICD shocks due to monomorphic VT despite antiarrhythmic drug therapy. It directly targets the arrhythmogenic substrate and offers the best chance of durable suppression.\\nOption A (increase amiodarone) risks further QT prolongation/toxicity without addressing the substrate. B (mexiletine) may be adjunctive but is not first-line definitive therapy in this storm context. D (dofetilide) is inappropriate: used for AF, not VT, and QTc already prolonged. E (ranolazine) has limited and non–guideline-based evidence for VT suppression.\\nNo internal contradictions or missing critical data; the scenario clearly fits indications for ablation and makes other options comparatively inferior.\\nMinimal fix: Explicitly state “meets criteria for electrical storm” in the stem to tighten the link to guideline language, though current wording is already adequate.\",\"medical_accuracy_score\":\"5\",\"logical_validity\":true,\"logical_false_reason\":\"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V\nVerdict on keyed answer: Correct best\nKey stem clues: Ischemic cardiomyopathy with severely reduced LVEF (28%), ICD in place, three appropriate therapies for monomorphic VT over 24 hours, already on substantial-dose amiodarone (400 mg/d), hemodynamically stable, QTc 485 ms, normal electrolytes and thyroid. These define electrical storm refractory to amiodarone in a structural heart disease patient.\nCatheter ablation (C) is guideline-supported as a class I indication for patients with electrical storm or recurrent ICD shocks due to monomorphic VT despite antiarrhythmic drug therapy. It directly targets the arrhythmogenic substrate and offers the best chance of durable suppression.\nOption A (increase amiodarone) risks further QT prolongation/toxicity without addressing the substrate. B (mexiletine) may be adjunctive but is not first-line definitive therapy in this storm context. D (dofetilide) is inappropriate: used for AF, not VT, and QTc already prolonged. E (ranolazine) has limited and non–guideline-based evidence for VT suppression.\nNo internal contradictions or missing critical data; the scenario clearly fits indications for ablation and makes other options comparatively inferior.\nMinimal fix: Explicitly state “meets criteria for electrical storm” in the stem to tighten the link to guideline language, though current wording is already adequate.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed127", "question_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed127-007", "question": "A 14-year-old girl presents with 6 months of progressive proximal muscle weakness, heliotrope rash, and Gottron papules. She has difficulty climbing stairs and raising her arms. Laboratory studies show CK 4,200 U/L and positive anti-MDA5 antibodies. Chest CT reveals subtle ground-glass opacities in bilateral lower lobes. Pulmonary function tests show FVC 72% predicted and DLCO 58% predicted. Muscle biopsy shows perifascicular atrophy. Which of the following findings most significantly increases her risk of rapidly progressive interstitial lung disease?", "options": ["Elevated serum ferritin level", "Presence of mechanic's hands", "Positive anti-Jo-1 antibodies", "Calcinosis cutis on examination", "Elevated aldolase level"], "answer": "A", "answer_index": 0, "explanation": "Anti-MDA5 antibody-positive dermatomyositis is associated with rapidly progressive interstitial lung disease (RP-ILD), which can be fatal. Elevated serum ferritin is a biomarker strongly associated with RP-ILD severity and poor prognosis in anti-MDA5 positive patients, reflecting macrophage activation. Anti-Jo-1 is associated with ILD but typically a more chronic course. Mechanic's hands are associated with antisynthetase syndrome. Calcinosis and elevated aldolase are features of juvenile DM but not specific predictors of RP-ILD in anti-MDA5 disease.", "generator_model": "claude-opus-4-5-20251101", "seed": 127, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "gpt-5.1-2025-11-13", "judge_model_outputs_raw": "{\"analysis\":\"Validity label: V\\nVerdict on keyed answer: Correct best\\nKey stem clues: 14-year-old with classic dermatomyositis manifestations (heliotrope rash, Gottron papules, perifascicular atrophy) plus positive anti-MDA5 antibodies and evidence of early interstitial lung disease (ground-glass opacities, reduced DLCO). In anti-MDA5–positive dermatomyositis, elevated serum ferritin is a well-recognized biomarker of macrophage activation and is strongly associated with rapidly progressive ILD and poor prognosis.\\nChoice analysis: (A) Elevated serum ferritin is specifically linked to RP-ILD severity in anti-MDA5 DM and is the strongest prognostic marker listed. (B) Mechanic’s hands are typical of antisynthetase syndrome and anti–tRNA synthetase antibodies, not specifically of RP-ILD in MDA5 disease. (C) Anti–Jo-1 antibodies are associated with ILD but more chronic, not specifically rapidly progressive ILD in this context. (D) Calcinosis cutis is a feature of juvenile DM but not a recognized predictor of RP-ILD. (E) Elevated aldolase parallels muscle inflammation/CK and is not a validated marker of RP-ILD.\\nMain issues: Stem and explanation are medically sound and specific; no major logical or medical flaws.\\nMinimal fix: None required; optionally add ferritin level value in stem to reinforce association with RP-ILD risk stratification.\",\"medical_accuracy_score\":\"5\",\"logical_validity\":true,\"logical_false_reason\":\"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V\nVerdict on keyed answer: Correct best\nKey stem clues: 14-year-old with classic dermatomyositis manifestations (heliotrope rash, Gottron papules, perifascicular atrophy) plus positive anti-MDA5 antibodies and evidence of early interstitial lung disease (ground-glass opacities, reduced DLCO). In anti-MDA5–positive dermatomyositis, elevated serum ferritin is a well-recognized biomarker of macrophage activation and is strongly associated with rapidly progressive ILD and poor prognosis.\nChoice analysis: (A) Elevated serum ferritin is specifically linked to RP-ILD severity in anti-MDA5 DM and is the strongest prognostic marker listed. (B) Mechanic’s hands are typical of antisynthetase syndrome and anti–tRNA synthetase antibodies, not specifically of RP-ILD in MDA5 disease. (C) Anti–Jo-1 antibodies are associated with ILD but more chronic, not specifically rapidly progressive ILD in this context. (D) Calcinosis cutis is a feature of juvenile DM but not a recognized predictor of RP-ILD. (E) Elevated aldolase parallels muscle inflammation/CK and is not a validated marker of RP-ILD.\nMain issues: Stem and explanation are medically sound and specific; no major logical or medical flaws.\nMinimal fix: None required; optionally add ferritin level value in stem to reinforce association with RP-ILD risk stratification.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed127", "question_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed127-008", "question": "A 42-year-old woman presents to the emergency department with acute chest pain and dyspnea. She has a history of antiphospholipid syndrome with prior deep vein thrombosis, currently on warfarin with INR 2.8. ECG shows sinus tachycardia with new right bundle branch block. CT pulmonary angiography reveals bilateral pulmonary emboli with right ventricular dilation. Troponin I is 0.89 ng/mL. Blood pressure is 88/54 mmHg, heart rate 118 bpm. Despite 2 liters of crystalloid, blood pressure remains 84/52 mmHg. Which of the following is the most appropriate next step?", "options": ["Initiate unfractionated heparin infusion", "Administer systemic alteplase", "Perform catheter-directed thrombolysis", "Emergent surgical embolectomy", "Initiate norepinephrine and observe"], "answer": "B", "answer_index": 1, "explanation": "This patient has high-risk (massive) pulmonary embolism with hemodynamic instability (persistent hypotension despite fluid resuscitation) and RV dysfunction. Systemic thrombolysis with alteplase is the first-line treatment for hemodynamically unstable PE per guidelines, even in anticoagulated patients, as the mortality benefit outweighs bleeding risk. The therapeutic INR does not preclude thrombolysis in this life-threatening situation. Catheter-directed therapy or surgical embolectomy are alternatives if thrombolysis is contraindicated or fails. Simply adding vasopressors without addressing the obstruction is inadequate.", "generator_model": "claude-opus-4-5-20251101", "seed": 127, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "gpt-5.1-2025-11-13", "judge_model_outputs_raw": "{\"analysis\":\"Validity label: V\\nVerdict on keyed answer: Correct best\\nKey stem clues: Acute dyspnea and chest pain; history of antiphospholipid syndrome; on warfarin with therapeutic INR (2.8); CT angiography showing bilateral PE with right ventricular dilation; ECG with new RBBB; elevated troponin; hypotension (88/54 → 84/52 mmHg) persisting despite 2 L crystalloid. These define high‑risk (massive) pulmonary embolism with RV dysfunction and refractory hypotension.\\nSystemic thrombolysis is guideline‑recommended first‑line therapy for hemodynamically unstable PE, and the presence of therapeutic warfarin is a relative, not absolute, contraindication when the situation is life‑threatening. Thus option B (systemic alteplase) is the single best answer.\\nOption A: UFH alone is inadequate for massive PE with ongoing shock. C and D: catheter‑directed or surgical embolectomy are reserved for thrombolysis contraindication or failure, not first‑line here. E: vasopressors without reperfusion therapy does not treat the underlying obstruction.\\nNo internal contradictions; details support a unique best answer. Medical content is accurate and consistent with major guidelines.\\nMinimal fix: Explicitly label the PE as “massive (high‑risk) pulmonary embolism with obstructive shock” to reinforce the intended risk category and reduce any ambiguity in interpretation.\",\"medical_accuracy_score\":\"5\",\"logical_validity\":true,\"logical_false_reason\":\"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V\nVerdict on keyed answer: Correct best\nKey stem clues: Acute dyspnea and chest pain; history of antiphospholipid syndrome; on warfarin with therapeutic INR (2.8); CT angiography showing bilateral PE with right ventricular dilation; ECG with new RBBB; elevated troponin; hypotension (88/54 → 84/52 mmHg) persisting despite 2 L crystalloid. These define high‑risk (massive) pulmonary embolism with RV dysfunction and refractory hypotension.\nSystemic thrombolysis is guideline‑recommended first‑line therapy for hemodynamically unstable PE, and the presence of therapeutic warfarin is a relative, not absolute, contraindication when the situation is life‑threatening. Thus option B (systemic alteplase) is the single best answer.\nOption A: UFH alone is inadequate for massive PE with ongoing shock. C and D: catheter‑directed or surgical embolectomy are reserved for thrombolysis contraindication or failure, not first‑line here. E: vasopressors without reperfusion therapy does not treat the underlying obstruction.\nNo internal contradictions; details support a unique best answer. Medical content is accurate and consistent with major guidelines.\nMinimal fix: Explicitly label the PE as “massive (high‑risk) pulmonary embolism with obstructive shock” to reinforce the intended risk category and reduce any ambiguity in interpretation.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed127", "question_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed127-009", "question": "A 28-year-old woman with Graves' disease treated with methimazole 30 mg daily for 8 weeks presents with fever (39.2°C), severe sore throat, and malaise for 2 days. Physical examination reveals pharyngeal erythema without exudate and no lymphadenopathy. Complete blood count shows WBC 1,200/μL with absolute neutrophil count 80/μL, hemoglobin 13.2 g/dL, and platelets 245,000/μL. Which of the following is the most appropriate immediate management?", "options": ["Discontinue methimazole and initiate propylthiouracil", "Discontinue methimazole, obtain blood cultures, and initiate broad-spectrum antibiotics with G-CSF", "Continue methimazole at reduced dose with close monitoring", "Discontinue methimazole and proceed with urgent thyroidectomy", "Discontinue methimazole and initiate lithium carbonate"], "answer": "B", "answer_index": 1, "explanation": "This patient has methimazole-induced agranulocytosis (ANC <500/μL), a rare but life-threatening complication occurring in 0.1-0.5% of patients, typically within the first 3 months. Management requires immediate discontinuation of the offending thionamide (cross-reactivity precludes switching to PTU), blood cultures, broad-spectrum antibiotics covering Pseudomonas given febrile neutropenia, and G-CSF to accelerate neutrophil recovery. Continuing or reducing methimazole is dangerous. Urgent thyroidectomy in an agranulocytic patient carries prohibitive infection risk. Alternative thyroid control can be achieved with beta-blockers, iodine, or lithium after stabilization.", "generator_model": "claude-opus-4-5-20251101", "seed": 127, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "gpt-5.1-2025-11-13", "judge_model_outputs_raw": "{\"analysis\":\"Validity label: V\\nVerdict on keyed answer: Correct best\\nKey stem clues: Recent initiation of high-dose methimazole (30 mg) with 8 weeks of therapy, acute onset of high fever and sore throat, WBC 1,200/μL with absolute neutrophil count 80/μL, otherwise normal hemoglobin and platelets. This clearly indicates methimazole-induced agranulocytosis with febrile neutropenia.\\nOption B correctly specifies immediate discontinuation of methimazole, blood cultures, broad-spectrum antibiotics appropriate for febrile neutropenia, and G-CSF, which is standard management for antithyroid drug–induced agranulocytosis in a febrile patient.\\nOption A is contraindicated because of cross-reactivity between thionamides; switching to PTU is unsafe. Option C is dangerous because continuation of the offending agent in agranulocytosis is unacceptable. Option D (urgent thyroidectomy) is not immediate priority and is high risk in a severely neutropenic, acutely ill patient. Option E omits essential sepsis/febrile neutropenia management and G-CSF, so is clearly inferior as an “immediate” step.\\nNo major medical inaccuracies are present; management aligns with standard endocrine and hematologic practice. \\nMinimal fix: Add “hemodynamically stable” to the stem if desired, but not necessary for discrimination; question is already clear and valid.\",\"medical_accuracy_score\":\"5\",\"logical_validity\":true,\"logical_false_reason\":\"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V\nVerdict on keyed answer: Correct best\nKey stem clues: Recent initiation of high-dose methimazole (30 mg) with 8 weeks of therapy, acute onset of high fever and sore throat, WBC 1,200/μL with absolute neutrophil count 80/μL, otherwise normal hemoglobin and platelets. This clearly indicates methimazole-induced agranulocytosis with febrile neutropenia.\nOption B correctly specifies immediate discontinuation of methimazole, blood cultures, broad-spectrum antibiotics appropriate for febrile neutropenia, and G-CSF, which is standard management for antithyroid drug–induced agranulocytosis in a febrile patient.\nOption A is contraindicated because of cross-reactivity between thionamides; switching to PTU is unsafe. Option C is dangerous because continuation of the offending agent in agranulocytosis is unacceptable. Option D (urgent thyroidectomy) is not immediate priority and is high risk in a severely neutropenic, acutely ill patient. Option E omits essential sepsis/febrile neutropenia management and G-CSF, so is clearly inferior as an “immediate” step.\nNo major medical inaccuracies are present; management aligns with standard endocrine and hematologic practice. \nMinimal fix: Add “hemodynamically stable” to the stem if desired, but not necessary for discrimination; question is already clear and valid.", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}, {"quiz_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed127", "question_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed127-010", "question": "A 9-year-old boy with a history of Kawasaki disease at age 2 (treated with IVIG and aspirin, with documented giant coronary artery aneurysms) presents for routine cardiology follow-up. He is asymptomatic and active without limitations. Current medications include aspirin 81 mg daily and clopidogrel 75 mg daily. Echocardiography shows a 9 mm right coronary artery aneurysm (z-score +12) and 7 mm left anterior descending aneurysm (z-score +9). Stress MRI perfusion shows no inducible ischemia. Which of the following additional interventions is most strongly recommended based on current guidelines?", "options": ["Addition of warfarin with target INR 2.0-3.0", "Discontinuation of clopidogrel given no ischemia", "Annual exercise stress testing only", "Coronary CT angiography every 5 years", "Restriction from all competitive sports"], "answer": "A", "answer_index": 0, "explanation": "Giant coronary artery aneurysms (z-score ≥10 or absolute diameter ≥8mm) represent the highest risk category in Kawasaki disease and require triple antithrombotic therapy: aspirin, a second antiplatelet agent (clopidogrel), AND systemic anticoagulation with warfarin (target INR 2.0-3.0) or LMWH per AHA guidelines. This is due to high thrombotic risk within aneurysms. The absence of current ischemia does not reduce thrombotic risk. These patients require activity restriction from contact/collision sports but the antithrombotic intensification is the most critical missing intervention.", "generator_model": "claude-opus-4-5-20251101", "seed": 127, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "judge_model": "gpt-5.1-2025-11-13", "judge_model_outputs_raw": "{\"analysis\":\"Validity label: V\\nVerdict on keyed answer: Correct best\\nKey stem clues: Prior Kawasaki disease with “documented giant coronary artery aneurysms”; current echo with 9 mm RCA (z-score +12) and 7 mm LAD (z-score +9); currently only on dual antiplatelet therapy (aspirin + clopidogrel); asymptomatic; no inducible ischemia on stress imaging. According to AHA Kawasaki disease guidelines, giant aneurysms (z-score ≥10 or diameter ≥8 mm) are highest risk and warrant systemic anticoagulation in addition to antiplatelet therapy.\\nOption A (add warfarin, INR 2–3) directly addresses the guideline-recommended escalation to triple therapy for giant aneurysms, making it the single best answer. B is incorrect because thrombotic risk persists despite absent ischemia; clopidogrel should not be stopped. C and D are plausible components of long-term surveillance but are not the “most strongly recommended additional intervention” in a child with giant aneurysms and no current anticoagulation. E overstates activity restriction; guidelines typically limit high-intensity/contact sports, not all competitive activity.\\nMain medical issue: None; rationale and key align with current consensus. Minimal fix: Cite “per current AHA Kawasaki disease guidelines” explicitly in stem to reinforce guideline basis, though not strictly necessary.\\n\",\"medical_accuracy_score\":\"5\",\"logical_validity\":true,\"logical_false_reason\":\"T\"}", "judge_output_valid": true, "judge_parse_error": null, "judge_json": {"analysis": "Validity label: V\nVerdict on keyed answer: Correct best\nKey stem clues: Prior Kawasaki disease with “documented giant coronary artery aneurysms”; current echo with 9 mm RCA (z-score +12) and 7 mm LAD (z-score +9); currently only on dual antiplatelet therapy (aspirin + clopidogrel); asymptomatic; no inducible ischemia on stress imaging. According to AHA Kawasaki disease guidelines, giant aneurysms (z-score ≥10 or diameter ≥8 mm) are highest risk and warrant systemic anticoagulation in addition to antiplatelet therapy.\nOption A (add warfarin, INR 2–3) directly addresses the guideline-recommended escalation to triple therapy for giant aneurysms, making it the single best answer. B is incorrect because thrombotic risk persists despite absent ischemia; clopidogrel should not be stopped. C and D are plausible components of long-term surveillance but are not the “most strongly recommended additional intervention” in a child with giant aneurysms and no current anticoagulation. E overstates activity restriction; guidelines typically limit high-intensity/contact sports, not all competitive activity.\nMain medical issue: None; rationale and key align with current consensus. Minimal fix: Cite “per current AHA Kawasaki disease guidelines” explicitly in stem to reinforce guideline basis, though not strictly necessary.\n", "medical_accuracy_score": 5, "logical_validity": true, "logical_false_reason": "T", "verdict": "PASS", "fail_reason": "NA"}, "judge_verdict": "PASS", "judge_fail_reason": "NA", "judge_medical_accuracy_score": 5}]